Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-04-03Clinical Trial Update: S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.
A SWOG trial (NCT00919139) evaluating a blood/bone marrow repository from patients with multiple myeloma, smoldering myeloma, Waldenström's …
-
CLINICAL_TRIALS trial_result · 2015-03-30Clinical Trial Update: Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial of bendamustine hydrochloride combined with lenalidomide and dexamethasone for relapsed/refractory multiple myeloma has comp…
-
FDA approval · 2015-03-27FDA Approved: KYPROLIS — Supplemental Application (Onyx Pharmaceuticals, Inc.)
FDA approved a supplemental application for KYPROLIS (carfilzomib) filed by Onyx Pharmaceuticals, Inc., updating the drug’s labeling. The ac…
-
CLINICAL_TRIALS trial_result · 2015-03-27Clinical Trial Update: Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma [Phase 2]
Phase 2 trial evaluating green tea extract in patients with MGUS and/or smoldering multiple myeloma; the study was terminated with results p…
-
CLINICAL_TRIALS trial_result · 2015-03-27Clinical Trial Update: Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma [Phase 2]
Phase 2 trial update evaluating panobinostat in patients with relapsed and bortezomib-refractory multiple myeloma; results posted after comp…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-03-24Clinical Trial Update: A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). [Phase 3]
Phase 3 open-label, single-arm trial evaluating safety and efficacy of Plerixafor with G-CSF for front-line mobilization in lymphoma and mul…
-
CLINICAL_TRIALS withdrawal · 2015-03-24Clinical Trial Update: This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.
This entry describes an expanded-access, multi-center, single-arm, open-label study of plerixafor for patients with non-Hodgkin's lymphoma, …
-
CLINICAL_TRIALS trial_result · 2015-03-24Clinical Trial Update: Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).
Long-term follow-up study of multiple myeloma patients who received plerixafor or placebo in the AMD3100-3102 trial. The study status is COM…
-
CLINICAL_TRIALS other · 2015-03-24Clinical Trial Update: Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty. [NA]
The trial evaluating percutaneous balloon kyphoplasty for malignant vertebral fractures in patients with vertebral fracture and multiple mye…
-
CLINICAL_TRIALS trial_result · 2015-03-19Clinical Trial Update: An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma. [Phase 2]
A Phase 2 trial evaluated palbociclib in combination with Velcade (bortezomib) and dexamethasone in patients with multiple myeloma and has c…
-
CLINICAL_TRIALS trial_result · 2015-03-17Clinical Trial Update: FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 clinical trial update reporting on FR901228 for relapsed or refractory multiple myeloma; the study has completed.
-
CLINICAL_TRIALS trial_result · 2015-03-13Clinical Trial Update: Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating tivantinib for relapsed or relapsed and refractory multiple myeloma has completed with results posted in 2…
-
CLINICAL_TRIALS trial_result · 2015-03-10Clinical Trial Update: A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma [Phase 3]
A Phase 3 trial evaluating palifermin for reducing oral mucositis in patients with multiple myeloma has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2015-03-10Clinical Trial Update: Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma [Phase 1]
Phase 1 trial evaluating the combination of bortezomib and tipifarnib for relapsed or refractory multiple myeloma; the trial status is compl…
-
CLINICAL_TRIALS trial_result · 2015-03-09Clinical Trial Update: Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating the combination of melphalan and bortezomib given before autologous stem cell transplant in multiple myeloma; the…
-
CLINICAL_TRIALS trial_result · 2015-03-09Clinical Trial Update: Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant [Phase 2]
A Phase 2 trial evaluated a combination of bortezomib, lenalidomide, and dexamethasone in multiple myeloma patients undergoing stem cell tra…
-
CLINICAL_TRIALS trial_result · 2015-03-06Clinical Trial Update: S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma [Phase 3]
Phase 3 trial S9922 evaluating combination chemotherapy with filgrastim, with or without thalidomide, for refractory multiple myeloma has be…
-
CLINICAL_TRIALS trial_result · 2015-03-06Clinical Trial Update: S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis [Phase 2]
Phase 2 SWOG trial evaluating dexamethasone plus interferon alfa in AL amyloidosis has completed enrollment. The update does not provide det…
-
CLINICAL_TRIALS trial_result · 2015-03-06Clinical Trial Update: A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma [Phase 3]
Phase 3 trial evaluating bortezomib as consolidation therapy in multiple myeloma has completed; the update does not provide trial outcomes.
-
CLINICAL_TRIALS trial_result · 2015-03-06Clinical Trial Update: S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease
SWOG's S0334 trial, which analyzes chromosomal abnormalities in patients with newly diagnosed multiple myeloma and other blood diseases, has…
-
CLINICAL_TRIALS trial_result · 2015-03-06Clinical Trial Update: SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma [Phase 3]
The Phase 3 SWOG-9321 trial comparing high-dose melphalan with total body irradiation and transplant versus combination chemotherapy in untr…
-
CLINICAL_TRIALS withdrawal · 2015-03-06Clinical Trial Update: S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma [Phase 2]
A SWOG phase 2 trial evaluating a combination of bortezomib, thalidomide, lenalidomide, and autologous stem cell transplant for newly diagno…
-
CLINICAL_TRIALS trial_result · 2015-03-05Clinical Trial Update: Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma [Phase 3]
This is a Phase 3 trial update showing completion of consolidation therapy with bortezomib in elderly patients with multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2015-03-04Clinical Trial Update: A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma [Phase 3]
Phase 3 trial comparing Revlimid (lenalidomide) plus dexamethasone versus dexamethasone alone in previously treated multiple myeloma; result…
-
CLINICAL_TRIALS trial_result · 2015-03-04Clinical Trial Update: Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma [Phase 2]
Phase 2 trial of pomalidomide in gene expression profiling-defined high-risk multiple myeloma has completed; results posted in 2015.